Home › Chronic Inflammatory Demyelinating Polyradiculoneuropathy › Florida › Orlando
Chronic Inflammatory Demyelinating Polyradiculoneuropathy clinical trials in Orlando, FL
4 studies for Chronic Inflammatory Demyelinating Polyradiculoneuropathy are looking for participants at sites in and around Orlando (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RecruitingPhase 2
- Site Number - 1603, Maitland · 6 mi away
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RecruitingPhase 3
- AdventHealth Orlando- Site Number : 8400006, Orlando
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
RecruitingPhase 3
- Clinical Study Site, Maitland · 6 mi away
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
RecruitingPhase 3
- Neurology Associates, Maitland · 6 mi away
Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials in other cities
- New York City, NY7 studies
- Miami, FL6 studies
- Houston, TX6 studies
- Kansas City, KS5 studies
- Philadelphia, PA5 studies
- Indio, CA5 studies
- St. Louis, MO5 studies
- New Haven, CT5 studies
- Tampa, FL4 studies
- Cleveland, OH4 studies
- Milwaukee, WI4 studies
- Washington, DC4 studies
Other studies in Orlando
- Non-Small Cell Lung Cancer44 studies
- Obesity31 studies
- Metastatic Cancer29 studies
- Overweight27 studies
- Alzheimer's Disease25 studies
- Type 2 Diabetes24 studies
- Cancer (all types)24 studies
- Breast Cancer23 studies
- Ovarian Cancer22 studies
- Ulcerative Colitis22 studies
- Lung Cancer21 studies
- Colorectal Cancer19 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.